Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension

Keyphrases

• AAV1 100%
• ABCC4 100%
• Mrp4 100%
• Silencing RNA 100%
• Inhalable 100%
• Monocrotaline-induced Pulmonary Hypertension 100%
• High Dose 33%
• Gene Transfer 33%
• Pulmonary Hypertension 33%
• Monocrotaline 33%
• Pulmonary Vascular Remodeling 33%
• Gene-deficient Mice 16%
• Adenovirus 16%
• Hypertrophy 16%
• Therapeutic Potential 16%
• Smooth muscle Cells 16%
• Cardiac Hypertrophy 16%
• ATP-binding Cassette Transporter A1 (ABCA1) 16%
• Hypoxia Response 16%
• Smooth muscle Cell Proliferation 16%
• Pulmonary Artery Hypertension 16%
• Aerosolized 16%
• Right Ventricular Systolic Pressure 16%
• Induced Models 16%
• Cyclic nucleotides 16%
• Intratracheal Delivery 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Monocrotaline-Induced Pulmonary Hypertension 100%
• Multidrug Resistance Associated Protein 4 100%
• Pulmonary Hypertension 60%
• Gene Delivery 40%
• Monocrotaline 40%
• Hypoxia 20%
• Heart Ventricle Hypertrophy 20%
• ABC Transporter 20%
• Adeno Associated Virus 1 20%
• Vascular Remodeling 20%
• Cyclic Nucleotide 20%

Biochemistry, Genetics and Molecular Biology

• Small Interfering RNA 100%
• ABCC4 100%
• Drug Megadose 50%
• Cell Proliferation 25%
• Downregulation 25%
• Systolic Blood Pressure 25%
• ABC Transporter 25%
• ATP-binding Cassette Transporter 25%
• Adeno Associated Virus 1 25%
• Cyclic Nucleotide 25%